Oncopeptides (Q3 Update): Q/Q Growth Only 5%, but 2026 Looks Promising - Redeye

Redeye comments on Oncopeptides’ 3rd quarter report. Sales grew 5% versus Q2 2025. Operating costs amounted to SEK-67m, with an EBIT of SEK-47m. Although sales were below our forecast in Q3, we have expectations for higher growth in the coming quarters.

Länk till analysen i sin helhet: https://www.redeye.se/research/1135536/oncopeptides-q3-update-q-q-growth-only-5-but-2026-looks-promising?utm_source=finwire&utm_medium=RSS